Test Price
700 AED✅ Home Collection Available
Chromosome 13q Deletion (Del(13q)) Analysis – FISH Cytogenetics Test in Dubai
Executive Summary & Core Metrics
Precise FISH-based detection of chromosome 13q deletion for risk stratification in Multiple Myeloma and Chronic Lymphocytic Leukemia – 99.9% diagnostic sensitivity, ISO-accredited processing, and hospital-based bone marrow extraction per DHA oncology protocols.
- Accuracy: 99.9% diagnostic sensitivity via ISO-accredited Fluorescence In-Situ Hybridization (FISH).
- Logistics: Hospital Extraction Only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Guidance: Post-test telephonic clinical interpretation by a DHA-licensed Consultant Medical Genetics.
- Billing: Direct insurance verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Chromosome 13q Deletion (del(13q)) FISH test precisely identifies loss of the long arm of chromosome 13 in plasma cells or B‑lymphocytes using locus‑specific fluorescent probes. This deletion is a well‑established independent prognostic marker in Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) and directly influences risk‑adapted therapy selection per current DHA guidelines.
| Feature | Our Test (FISH) | Closest Alternative (Karyotyping) |
|---|---|---|
| Method | Fluorescence In‑Situ Hybridization (13q14 probes) | Conventional G‑banding karyotype |
| Sensitivity | ~99.9% (detects submicroscopic deletions) | ~60–70% (requires visible chromosomal changes) |
| Turnaround | 3–4 days | 10–14 days |
| Sample Type | Bone marrow (preferred) or peripheral blood | Bone marrow (fresh) mandatory |
Physician Insight & Safety Protocols
"The del(13q) FISH result must always be interpreted alongside the full cytogenetic panel (e.g., t(4;14), del(17p), 1q gain) and clinical parameters to accurately stratify risk and guide therapy. This test is a powerful tool in the oncologist's arsenal, but it never replaces comprehensive clinical judgment. Discuss your results with your treating physician for an integrated management plan."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Clinical Advisory
Do not discontinue or alter any prescribed medication without consulting your treating oncologist. This test is a prognostic indicator, not a replacement for ongoing clinical evaluation or treatment.
Exclusion Criteria & Emergency Red Flags
- Patients with hemodynamic instability, active uncontrolled infection, or known bleeding diathesis are not candidates for bone marrow aspiration.
- This test is indicated only upon oncologist prescription for MM/CLL workup and is not suitable for routine health screening.
- Emergency red flags after bone marrow collection: Seek immediate care if you develop severe persistent pain at the puncture site, active bleeding, fever >38°C, or signs of sepsis.
- Bone marrow aspiration must be performed under local anaesthesia in a hospital setting; a responsible adult should accompany you if sedation is used.
Patient FAQ & Clinical Guidance
1. What is the Del(13q) FISH test, and why is it important for MM and CLL?
This test uses fluorescent probes to directly visualize loss of the 13q14 region in malignant plasma cells (MM) or B‑lymphocytes (CLL). The presence of the deletion categorizes the disease as higher‑risk and influences whether more intensive therapy or closer surveillance is needed. It is a cornerstone of modern cytogenetic risk stratification.
2. How do I prepare for the test, and is it painful?
For a bone marrow aspirate, the site (typically the hip bone) is numbed with local anaesthetic; most patients feel pressure but not sharp pain. Peripheral blood collection is similar to a routine blood draw. A doctor’s prescription is mandatory. You will receive specific fasting instructions if sedation is planned – our team will advise during scheduling.
3. How reliable is the test, and what do the results mean?
The test achieves near‑complete accuracy for deletions larger than 200 kb. A positive result (deletion detected) indicates high‑risk disease; a negative result suggests standard risk, but must be interpreted alongside other cytogenetic and clinical markers. False positives/negatives are extremely rare with our ISO‑accredited methodology. Your oncologist will integrate the result into your personalised treatment plan.
UAE Regulatory & Data Privacy Adherence
This service complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring secure handling and confidentiality of your health information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the safe and ethical use of digital health data.
All test results are encrypted and shared only with authorised healthcare providers. For questions about your data rights, contact our Data Protection Officer at dpo@dnalabsuae.com.
Clinical & Logistical Metadata
| Test Name | Chromosome 13q Deletion (Del(13q)) Analysis (FISH) |
| Price (AED) | 700 |
| Turnaround Time | 3–4 days |
| Sample Type / Matrix | Bone Marrow (preferred) / Peripheral Blood – Hospital Extraction Only |
| Methodology Used | Fluorescence In-Situ Hybridization (FISH) – LSI 13q14 probe |
| ICD-10-CM Code | C90.0, C91.1 |
| LOINC Code | 61853-0 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians